Skip to main content

Table 2 Overall response rates

From: Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

 

Patients (n)

CR (%)

PR (%)

SD (%)

PD (%)

Overall

31

1 (3.2)

9 (29)

12 (38.8)

9 (29)

2nd and 3rd line

11

0 (0)

5 (45.5)

6 (55.5)

0 (0)

4th and later line

20

1 (5)

4 (20)

6 (30)

9 (45)

FOLFIRI

19

1 (5.3)

6 (31.6)

8 (42.1)

4 (2.1)

FOLFOX

12

0 (0)

3 (25)

4 (33.3)

5 (41.7)

Same CT previously used

     

   Yes

29

1 (3.5)

9 (31)

11 (37.9)

8 (27.6)

   No

2*

0 (0)

0 (0)

1 (50)

1 (50)

  1. CR; complete response, CT; chemotherapy; PR; partial response, SD; stable disease, PD; progression disease. * no previous treatment by FOLFOX in two patients treated by bevacizumab + FOLFOX